Clinical Significance of Combined Anti-Cyclic Citrullinated Peptide Antibody and Rheumatoid Factor Assays in Rheumatoid Arthritis Diagnosis
Objectives: This study aims to investigate the value of combined anti-cyclic citrullinated peptide (CCP) antibody and rheumatoid factor (RF) assays in the clinical diagnosis of patients with rheumatoid arthritis (RA). Patients and methods: Results of both anti-CCP and RF detection in 70 RA patients...
Gespeichert in:
| Veröffentlicht in: | Archives of rheumatology 2015-06, Vol.30 (2), p.104-108 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 108 |
|---|---|
| container_issue | 2 |
| container_start_page | 104 |
| container_title | Archives of rheumatology |
| container_volume | 30 |
| creator | Cao, Qingmei Wang, Yanfeng Jing, Yuanyuan |
| description | Objectives: This study aims to investigate the value of combined anti-cyclic citrullinated peptide (CCP) antibody and rheumatoid factor (RF) assays in the clinical diagnosis of patients with rheumatoid arthritis (RA). Patients and methods: Results of both anti-CCP and RF detection in 70 RA patients (13 males, 57 females; mean age 49.2 [+ or -] 12.1 years; range 35 to 61 years) and 112 non-RA patients (35 males, 77 females; mean age 42.5 [+ or -] 7.1 years; range 35 to 49 years) were retrospectively and statistically analyzed. Results: In RA patients, positive rates of anti-CCP and RF were 70.0% and 77.1%, respectively. These rates were significantly higher than the rates in non-RA patients (2.7% and 4.5%, respectively; p |
| doi_str_mv | 10.5606/ArchRheumatol.2015.4318 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_journals_1692740163</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A419763893</galeid><sourcerecordid>A419763893</sourcerecordid><originalsourceid>FETCH-LOGICAL-c502t-402ee5c0d35398437656ee7a32ac80d3849d20e1f3de2c90267f69f85549488e3</originalsourceid><addsrcrecordid>eNptkV2L1TAQhosoeFj3NxgQvOsxX02Ty1JdFRYUP65DNp2eztImxyS9OL_BP22Pq7gHZC5mmHnemYG3ql4yum8UVW-65KcvE6yLK3Hec8qavRRMP6l2TFBTU67F02rHmdR1Q6V6Xl3nfE8pZbJViopd9bOfMaB3M_mKh4DjVgYPJI6kj8sdBhhIFwrW_cnP6EmPJa3zJnFlm3yGY8EBfhN3cTgRFwby9x0cyI3zJSbS5exOmWB4POtSmRIWzOQtukOIGfOL6tno5gzXf_JV9f3m3bf-Q3376f3HvrutfUN5qSXlAI2ng2iE0VK0qlEArRPceb11tTQDp8BGMQD3hnLVjsqMummkkVqDuKpePew9pvhjhVzsfVxT2E5apgxvJWVK_KMObgaLYYwlOb9g9raTzLRKaHOm9v-hthhgQR8DjLj1LwSvHwkmcHOZcpzXgjHkS7B9AH2KOScY7THh4tLJMmrP5tsL8-3ZfHs2X_wCPSilSg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1692740163</pqid></control><display><type>article</type><title>Clinical Significance of Combined Anti-Cyclic Citrullinated Peptide Antibody and Rheumatoid Factor Assays in Rheumatoid Arthritis Diagnosis</title><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Cao, Qingmei ; Wang, Yanfeng ; Jing, Yuanyuan</creator><creatorcontrib>Cao, Qingmei ; Wang, Yanfeng ; Jing, Yuanyuan</creatorcontrib><description>Objectives: This study aims to investigate the value of combined anti-cyclic citrullinated peptide (CCP) antibody and rheumatoid factor (RF) assays in the clinical diagnosis of patients with rheumatoid arthritis (RA). Patients and methods: Results of both anti-CCP and RF detection in 70 RA patients (13 males, 57 females; mean age 49.2 [+ or -] 12.1 years; range 35 to 61 years) and 112 non-RA patients (35 males, 77 females; mean age 42.5 [+ or -] 7.1 years; range 35 to 49 years) were retrospectively and statistically analyzed. Results: In RA patients, positive rates of anti-CCP and RF were 70.0% and 77.1%, respectively. These rates were significantly higher than the rates in non-RA patients (2.7% and 4.5%, respectively; p<0.05). The sensitivity of combined anti-CCP and RF assays was 87.1% compared to the sensitivities of a single item assay of 70% and 77.1% for anti-CCP and RF, respectively. However, the combined assay had slightly lower specificity. With respect to the diagnostic index and rate of total consistency, the combined assay was superior to any single item assay. Conclusion: Combined anti-CCP and RF assays are more valuable in diagnosing RA than any single item assay. Keywords: Cyclic citrullinated peptide; rheumatoid arthritis; rheumatoid factor.</description><identifier>ISSN: 2148-5046</identifier><identifier>ISSN: 1309-0291</identifier><identifier>EISSN: 1309-0283</identifier><identifier>DOI: 10.5606/ArchRheumatol.2015.4318</identifier><language>eng</language><publisher>Istanbul: Turkish League Against Rheumatism</publisher><subject>Arthritis ; B cells ; Peptides ; Rheumatoid factor</subject><ispartof>Archives of rheumatology, 2015-06, Vol.30 (2), p.104-108</ispartof><rights>COPYRIGHT 2015 Turkish League Against Rheumatism</rights><rights>Copyright Prof Sebnem Ataman, President Turkish League Against Rheumatism 2015</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c502t-402ee5c0d35398437656ee7a32ac80d3849d20e1f3de2c90267f69f85549488e3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Cao, Qingmei</creatorcontrib><creatorcontrib>Wang, Yanfeng</creatorcontrib><creatorcontrib>Jing, Yuanyuan</creatorcontrib><title>Clinical Significance of Combined Anti-Cyclic Citrullinated Peptide Antibody and Rheumatoid Factor Assays in Rheumatoid Arthritis Diagnosis</title><title>Archives of rheumatology</title><description>Objectives: This study aims to investigate the value of combined anti-cyclic citrullinated peptide (CCP) antibody and rheumatoid factor (RF) assays in the clinical diagnosis of patients with rheumatoid arthritis (RA). Patients and methods: Results of both anti-CCP and RF detection in 70 RA patients (13 males, 57 females; mean age 49.2 [+ or -] 12.1 years; range 35 to 61 years) and 112 non-RA patients (35 males, 77 females; mean age 42.5 [+ or -] 7.1 years; range 35 to 49 years) were retrospectively and statistically analyzed. Results: In RA patients, positive rates of anti-CCP and RF were 70.0% and 77.1%, respectively. These rates were significantly higher than the rates in non-RA patients (2.7% and 4.5%, respectively; p<0.05). The sensitivity of combined anti-CCP and RF assays was 87.1% compared to the sensitivities of a single item assay of 70% and 77.1% for anti-CCP and RF, respectively. However, the combined assay had slightly lower specificity. With respect to the diagnostic index and rate of total consistency, the combined assay was superior to any single item assay. Conclusion: Combined anti-CCP and RF assays are more valuable in diagnosing RA than any single item assay. Keywords: Cyclic citrullinated peptide; rheumatoid arthritis; rheumatoid factor.</description><subject>Arthritis</subject><subject>B cells</subject><subject>Peptides</subject><subject>Rheumatoid factor</subject><issn>2148-5046</issn><issn>1309-0291</issn><issn>1309-0283</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNptkV2L1TAQhosoeFj3NxgQvOsxX02Ty1JdFRYUP65DNp2eztImxyS9OL_BP22Pq7gHZC5mmHnemYG3ql4yum8UVW-65KcvE6yLK3Hec8qavRRMP6l2TFBTU67F02rHmdR1Q6V6Xl3nfE8pZbJViopd9bOfMaB3M_mKh4DjVgYPJI6kj8sdBhhIFwrW_cnP6EmPJa3zJnFlm3yGY8EBfhN3cTgRFwby9x0cyI3zJSbS5exOmWB4POtSmRIWzOQtukOIGfOL6tno5gzXf_JV9f3m3bf-Q3376f3HvrutfUN5qSXlAI2ng2iE0VK0qlEArRPceb11tTQDp8BGMQD3hnLVjsqMummkkVqDuKpePew9pvhjhVzsfVxT2E5apgxvJWVK_KMObgaLYYwlOb9g9raTzLRKaHOm9v-hthhgQR8DjLj1LwSvHwkmcHOZcpzXgjHkS7B9AH2KOScY7THh4tLJMmrP5tsL8-3ZfHs2X_wCPSilSg</recordid><startdate>20150601</startdate><enddate>20150601</enddate><creator>Cao, Qingmei</creator><creator>Wang, Yanfeng</creator><creator>Jing, Yuanyuan</creator><general>Turkish League Against Rheumatism</general><general>Prof Sebnem Ataman, President Turkish League Against Rheumatism</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>EDSIH</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope></search><sort><creationdate>20150601</creationdate><title>Clinical Significance of Combined Anti-Cyclic Citrullinated Peptide Antibody and Rheumatoid Factor Assays in Rheumatoid Arthritis Diagnosis</title><author>Cao, Qingmei ; Wang, Yanfeng ; Jing, Yuanyuan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c502t-402ee5c0d35398437656ee7a32ac80d3849d20e1f3de2c90267f69f85549488e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Arthritis</topic><topic>B cells</topic><topic>Peptides</topic><topic>Rheumatoid factor</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cao, Qingmei</creatorcontrib><creatorcontrib>Wang, Yanfeng</creatorcontrib><creatorcontrib>Jing, Yuanyuan</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Turkey Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><jtitle>Archives of rheumatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cao, Qingmei</au><au>Wang, Yanfeng</au><au>Jing, Yuanyuan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical Significance of Combined Anti-Cyclic Citrullinated Peptide Antibody and Rheumatoid Factor Assays in Rheumatoid Arthritis Diagnosis</atitle><jtitle>Archives of rheumatology</jtitle><date>2015-06-01</date><risdate>2015</risdate><volume>30</volume><issue>2</issue><spage>104</spage><epage>108</epage><pages>104-108</pages><issn>2148-5046</issn><issn>1309-0291</issn><eissn>1309-0283</eissn><abstract>Objectives: This study aims to investigate the value of combined anti-cyclic citrullinated peptide (CCP) antibody and rheumatoid factor (RF) assays in the clinical diagnosis of patients with rheumatoid arthritis (RA). Patients and methods: Results of both anti-CCP and RF detection in 70 RA patients (13 males, 57 females; mean age 49.2 [+ or -] 12.1 years; range 35 to 61 years) and 112 non-RA patients (35 males, 77 females; mean age 42.5 [+ or -] 7.1 years; range 35 to 49 years) were retrospectively and statistically analyzed. Results: In RA patients, positive rates of anti-CCP and RF were 70.0% and 77.1%, respectively. These rates were significantly higher than the rates in non-RA patients (2.7% and 4.5%, respectively; p<0.05). The sensitivity of combined anti-CCP and RF assays was 87.1% compared to the sensitivities of a single item assay of 70% and 77.1% for anti-CCP and RF, respectively. However, the combined assay had slightly lower specificity. With respect to the diagnostic index and rate of total consistency, the combined assay was superior to any single item assay. Conclusion: Combined anti-CCP and RF assays are more valuable in diagnosing RA than any single item assay. Keywords: Cyclic citrullinated peptide; rheumatoid arthritis; rheumatoid factor.</abstract><cop>Istanbul</cop><pub>Turkish League Against Rheumatism</pub><doi>10.5606/ArchRheumatol.2015.4318</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2148-5046 |
| ispartof | Archives of rheumatology, 2015-06, Vol.30 (2), p.104-108 |
| issn | 2148-5046 1309-0291 1309-0283 |
| language | eng |
| recordid | cdi_proquest_journals_1692740163 |
| source | EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Arthritis B cells Peptides Rheumatoid factor |
| title | Clinical Significance of Combined Anti-Cyclic Citrullinated Peptide Antibody and Rheumatoid Factor Assays in Rheumatoid Arthritis Diagnosis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T05%3A14%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20Significance%20of%20Combined%20Anti-Cyclic%20Citrullinated%20Peptide%20Antibody%20and%20Rheumatoid%20Factor%20Assays%20in%20Rheumatoid%20Arthritis%20Diagnosis&rft.jtitle=Archives%20of%20rheumatology&rft.au=Cao,%20Qingmei&rft.date=2015-06-01&rft.volume=30&rft.issue=2&rft.spage=104&rft.epage=108&rft.pages=104-108&rft.issn=2148-5046&rft.eissn=1309-0283&rft_id=info:doi/10.5606/ArchRheumatol.2015.4318&rft_dat=%3Cgale_proqu%3EA419763893%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1692740163&rft_id=info:pmid/&rft_galeid=A419763893&rfr_iscdi=true |